Tradjenta contains linagliptin as its active component. It belongs to the therapeutic class of diabetes management and is marketed as a 5 mg pill. In Hong Kong, Tradjenta is a prescription-only medication (Rx) approved by the Hong Kong Department of Health. The brand is manufactured by Boehringer Ingelheim and is also available in generic form under the name linagliptin.
Linagliptin is a highly selective dipeptidyl-peptidase-4 (DPP-4) inhibitor. By blocking the DPP-4 enzyme, it prolongs the activity of incretin hormones-mainly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner, which helps lower blood glucose levels after meals.
Linagliptin has a high affinity for DPP-4 and is eliminated primarily via the biliary-intestinal route, allowing it to be used without dosage adjustment in patients with renal impairment.
Regulatory agencies in Hong Kong and internationally (FDA, EMA) have approved Tradjenta specifically for the management of T2DM. It is not indicated for type 1 diabetes or for diabetic ketoacidosis.
If any of these conditions apply, clinicians must weigh the risks and benefits before prescribing.
These effects are reported in >1 % of patients in clinical trials.
Note: Patients should provide a full medication list (prescription, over-the-counter, supplements, herbal products) to their healthcare provider before initiating Tradjenta.
Regular follow-up with a healthcare professional ensures optimal glycemic control and early detection of any adverse events.
This article provides educational information about Tradjenta and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
The tablet is typically imprinted with “5 MG” on one side and “TRADJENTA” on the other, allowing easy visual identification.
Yes, but carry the medication in its original packaging with a copy of the prescription. Some countries may require a physician’s note; check the destination’s import regulations beforehand.
Linagliptin is not a prohibited substance under the World Anti-Doping Agency (WADA) list. However, athletes should verify with their governing body before use.
Formulation (5 mg tablet) and active ingredient are the same globally, but inactive excipients may vary slightly to meet local regulatory requirements.
All DPP-4 inhibitors share the same mechanism, but linagliptin is unique in its primarily biliary excretion, allowing use without renal dose adjustment-a potential advantage in patients with kidney disease.
Report persistent or worsening joint pain to your healthcare provider promptly, as it may be an uncommon adverse effect that requires evaluation.
Tradjenta tablets are designed for whole-tablet ingestion; crushing or splitting may affect drug absorption and is not recommended.
No routine dose reduction is required for older adults, but clinicians should monitor renal function and overall health status regularly.
Generic linagliptin typically costs less than the brand name Tradjenta, though exact pricing varies by pharmacy and insurance coverage. Patients should discuss affordable options with their prescriber or pharmacist.
